Scripps VIVO

Academic Article RDF

• 40
• 41
• 42
• 43
• 44
• 45
• 46
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• 56
• 57
• 58
• 59
• 60
• 61
• 62
• 63
• 64
• 65
• 66
• 67
• 68
• 69
• 70
• 71
• 72
• 73
• 74
• 75
• 76
• 77
• 78
• 79
• 80
• more...

• A peptide that antagonizes tcr-mediated reactions with both syngeneic and allogeneic agonists: Functional and structural aspects
• A peptide-free, liposome-based oligosaccharide vaccine, adjuvanted with a natural killer T cell antigen, generates robust antibody responses
• A peptide-major histocompatibility complex II chimera favors survival of pancreatic beta-islets grafted in type 1 diabetic mice
• A peptidomics strategy to elucidate the proteolytic pathways that inactivate peptide hormones
• A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity
• A peptoid antagonist of VEGF receptor 2 recognizes a 'hotspot' in the extracellular domain distinct from the hormone-binding site
• A PERIOD inhibitor buffer introduces a delay mechanism for CLK/CYC-activated transcription
• A peripheral and central t-cell antigen recognized by a monoclonal thymocytotoxic autoantibody from new-zealand black mice
• A periplasmic reducing system protects single cysteine residues from oxidation
• A permutation test for stabilization of polypeptide helices by sequence-dependent side chain interactions: Characterization of a helix initiation site within the myohemerythrin sequence 76-87
• A permutational approach toward protein-DNA recognition
• A persistent RNA-DNA hybrid is formed during transcription at a phylogenetically conserved mitochondrial DNA sequence
• A perspective on mechanisms of protein tetramer formation
• A perspective on the structural and functional constraints for immune evasion: insights from influenza virus
• A PET imaging strategy for interrogating target engagement and oncogene status in pancreatic cancer
• A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
• A ph sensitive colorometric assay for the high-throughput screening of enzyme inhibitors and substrates: A case study using kinases
• A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries
• A phage display system with unnatural amino acids
• A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone
• A pharmacological network for lifespan extension in Caenorhabditis elegans
• A pharmacophore modeling approach to design new taxol (R) mimics: towards the synthesis of potential anticancer and MDR-reversing agent
• A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
• A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
• A phase i clinical trial of the hu14.18-il2 (emd 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the children's oncology group
• A phase i/ib trial of murine monoclonal anti-gd2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma - a report of the children's cancer group
• A phase I/II trial of nimodipine for HIV-related neurologic complications
• A phase-i study of human mouse chimeric antiganglioside gd2 antibody ch14.18 in patients with neuroblastoma
• A phase-i study of neuroblastoma with the antiganglioside gd2 antibody 14.G2a
• A phenotype survey of 36 mutant mouse strains with gene-targeted defects in glycosyltransferases or glycan-binding proteins

• 40
• 41
• 42
• 43
• 44
• 45
• 46
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• 56
• 57
• 58
• 59
• 60
• 61
• 62
• 63
• 64
• 65
• 66
• 67
• 68
• 69
• 70
• 71
• 72
• 73
• 74
• 75
• 76
• 77
• 78
• 79
• 80
• more...